Unlearn.AI, which creates “digital twin” profiles of patients in clinical trials, raised $15M at a $265M valuation and adds OpenAI CTO Mira Murati to its board
Unlearn.AI, which has built a machine learning platform that creates “digital twin” profiles of patients in clinical trials …
Context & Ripple Effects
Unlearn.AI has been building its patient "digital twin" platform in public for three years before this round: a $12M Series A in 2020 framed the software as a way to reduce human participation in trials, and a $50M Series B led by Insight Partners in 2022 scaled it. This $15M raise at a $265M valuation is smaller than that Series B but adds a different kind of asset — OpenAI CTO Mira Murati joining the board, tying a clinical-trials AI vendor to the most prominent lab in the field.
The category validation is visible in what follows: Unlearn went on to raise a $50M Series C in 2024, pushing total funding past $130M, and the digital-twin thesis spread beyond trials — Twin Health raised a $53M Series E at a $950M valuation applying the same idea to diabetes and metabolic care. The Murati appointment reads as an early signal of that mainstreaming.
First-order effects
- Unlearn gains $15M of runway and a board seat held by OpenAI's CTO — a credibility signal for pharma sponsors evaluating whether its digital twins can stand in for control-arm patients.
- Trial sponsors using Unlearn's platform can run smaller studies, since the software generates digital twin profiles that substitute for some enrolled participants.
Second-order effects
- Investors treat digital twins as a category, not a one-off: Twin Health's later $53M raise at a $950M valuation shows the same AI-twin thesis attracting growth capital in adjacent patient-facing markets, not just trial tooling.
- Clinical research incumbents face pressure to offer AI-simulated comparators or cede the smaller-faster-trial pitch to vendors like Unlearn.
Third-order effects
- If the funding arc holds — $12M, then $50M, then this round, then $50M more for $130M+ total — clinical trials structurally shift toward hybrid designs where AI-generated patient profiles substitute for part of the control arm, with regulators and pharma sponsors deciding how much synthetic evidence counts.
- The OpenAI linkage points to a pattern where frontier-lab leadership migrates onto boards of vertical AI companies, concentrating model-layer influence across healthcare AI.
The trend: Digital-twin AI is expanding from a clinical-trial niche into a funded healthcare category, with frontier-lab affiliations and successive raises marking its move toward mainstream trial design.